AI Can Summarize Research, But It Can’t Tell You What Experts Actually Think
A few years ago, a first look at a disease area meant a week of searching, reading and copying numbers into a spreadsheet, then hoping you hadn’t missed the one paper that mattered. Today you can type ...
Five Commercialization Mistakes Biotech Companies Make Before Launch (And a Checklist to Avoid Them)
Getting a drug approved is brutal. According to Tufts CSDD, only about 12% of drug candidates that enter clinical trials are ultimately approved, and CSDD's analysis put the full lifecycle cost of bri ...
Why Promising Drugs Struggle After FDA Approval: Understanding the Barriers to Market Success
For most drug developers, FDA approval feels like the finish line. Then launch day arrives and the real test begins.FDA approval confirms that a drug has met the applicable regulatory requirements for ...
Trends in HEOR: What Payers and HTA Bodies Are Asking for Now
A therapy can clear every regulatory hurdle and still face difficult questions at the formulary or reimbursement stage. That gap between regulatory approval and patient access is where health economic ...
Evidence Without Context: Why Advanced Analytics Still Miss Commercial Reality
Advanced analytics has transformed how life sciences teams generate evidence. We can analyze massive datasets, model future markets, and simulate treatment pathways with remarkable precision. Yet desp ...
Beyond GLP-1s: Inside Obesity’s $80 Billion Second Wave
The first wave of obesity innovation proved a simple point: meaningful weight loss can be delivered at scale if patients can start therapy, stay on it, and afford it. GLP-1s turned obesity into one of ...
ESMO 2026 Preview: What the Abstracts Reveal Before the Data Drops
Every major oncology congress has its headline moments: a trial that changes practice, a therapy that exceeds expectations, or a new mechanism that suddenly becomes the industry's next big focus.But E ...
How Patient Journey Analytics Improves Drug Commercialization
A drug's clinical trial data tells you how it performs under ideal conditions. It doesn't tell you where your patients actually are, why they're taking three years to get diagnosed, which physicians a ...
Clinical Differentiation Is No Longer Enough: How “Access Differentiation” Is Becoming the Real Moat
A therapy can post best-in-class trial data and still stall at launch. Not because the science was wrong, but because nobody could tell a payer what happens after the trial ends, when the drug meets r ...
Can Premium Pricing Survive in Rare Diseases? What 2026 Signals Say
For nearly two decades, rare diseases have lived in a pricing exception zone. Small patient populations, high unmet need, limited competition, and outcomes that could genuinely change a patient's life ...